Collegium Pharma (COLL) Announces FDA Won't Complete Review of Xtampza ...
StreetInsider.com
Collegium Pharma (NASDAQ: COLL) announced that the U.S. Food and Drug Administration (FDA) has advised Collegium that it will not be able to complete its review of the New Drug Application (NDA) for Xtampza™ ER (oxycodone) extended-release ...